EU-OS provides world-class services to academia and industry in the fields of small molecule screening and medicinal chemistry. Thereby, it promotes the rich chemical knowledge of Europe and enables systematic studies of the bioactivities of a larger collection of compounds leading to ground-breaking insights into cellular and organismal metabolic or signalling pathways. After careful consideration of IPR from all stakeholders involved, all results will eventually become available to the public. EU-OS will thereby also play an increasingly important role in facilitating the drug discovery process in Europe. In addition, it also has a great potential for innovative development of biomarkers and other diagnostics.
EU-OS-DRIVE will further help the EU-OS-ERIC to deliver its added-value via constant re-use of generated data and tools by users across the globe and to support the competitiveness of European life science industries.
EU-OS developed its concept and business plan during the preparatory phase and has received information on the Commission Implementing Decision on setting up the EU-OS European Research Infrastructure Consortium (EU-OS-ERIC) in March 2018. In 2018, EU-OS started its ERIC operations with seven founding members and one observer. Since 2019, EU-OS counts 8 member countries.
Submit your proposal now to get access to our small molecule screening or chemical proteomics capacities.